S. Castiglioni

Stereotactic Body Radiation Therapy With Ablative Dose on Liver Metastases: Radiation-induced Liver Disease (RILD) and Toxicity Assessment

to discontinuation of sorafenib prior to RT due to sorafenib toxicity. Two other patients (1-level 2, 1-level 3) had sorafenib dose reductions to 200 mg daily due to sorafenib toxicity, without DLT. Three patients developed transient grade 3 chest wall pain (1-level 1, 2-level 2). Median survival was 14.0 months. In the WLRT strata, 2 grade 5 liver DLTs were seen: 1 of 6 evaluable patients at level 1, and 1 of 5 evaluable patients at level 2 (2 patients at 2-month follow-up). One grade 3 pneumonitis (level 2) and 1 chest wall pain (level 2) were also seen. Four additional WLRT patients died of other causes during RT (urosepsis, level 1) and at 3-3.5 months from progressive disease. Median survival of WLRT patients was 5.8 months. Conclusions: Full dose sorafenib can be combined safely with SBRT, although chest wall toxicity is increased. Serious toxicity was seen following low dose sorafenib combined with whole liver RT at 21.6 Gy. Author Disclosure: A.M. Brade: None. J. Kim: None. J. Brierley: None. R. Dinniwell: None. R. Wong: None. C. Cho: None. Z. Kassam: None. A. Joshua: None. J. Knox: None. L. Dawson: None.